NR4A1 and breast cancer: AR is ubiquitously expressed in 72–79% of primary breast cancers [3,4,5], although its expression differs by breast cancer subtype, and is more frequently expressed in hormone receptor positive breast cancer compared to hormone receptor negative breast cancer [5,6].